[go: up one dir, main page]

DE69122761D1 - Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes - Google Patents

Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes

Info

Publication number
DE69122761D1
DE69122761D1 DE69122761T DE69122761T DE69122761D1 DE 69122761 D1 DE69122761 D1 DE 69122761D1 DE 69122761 T DE69122761 T DE 69122761T DE 69122761 T DE69122761 T DE 69122761T DE 69122761 D1 DE69122761 D1 DE 69122761D1
Authority
DE
Germany
Prior art keywords
idd
dependent diabetes
early detection
insulin
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69122761T
Other languages
English (en)
Other versions
DE69122761T2 (de
Inventor
Mark Atkinson
Noel Maclaren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Publication of DE69122761D1 publication Critical patent/DE69122761D1/de
Application granted granted Critical
Publication of DE69122761T2 publication Critical patent/DE69122761T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
DE69122761T 1990-08-17 1991-08-16 Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes Expired - Lifetime DE69122761T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56932490A 1990-08-17 1990-08-17
PCT/US1991/005920 WO1992003733A1 (en) 1990-08-17 1991-08-16 Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus

Publications (2)

Publication Number Publication Date
DE69122761D1 true DE69122761D1 (de) 1996-11-21
DE69122761T2 DE69122761T2 (de) 1997-03-13

Family

ID=24274953

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69122761T Expired - Lifetime DE69122761T2 (de) 1990-08-17 1991-08-16 Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes

Country Status (10)

Country Link
EP (1) EP0543945B1 (de)
JP (1) JP2649103B2 (de)
AT (1) ATE144326T1 (de)
AU (1) AU661828B2 (de)
CA (1) CA2089742C (de)
DE (1) DE69122761T2 (de)
DK (1) DK0543945T3 (de)
ES (1) ES2093714T3 (de)
GR (1) GR3022078T3 (de)
WO (1) WO1992003733A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
EP0547164B1 (de) * 1990-09-07 2004-06-09 The Regents Of The University Of California Verfahren zur diagnose und behandlung von diabetes
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
JP3027190B2 (ja) * 1991-02-22 2000-03-27 アムラド・コーポレイション・リミテッド グルタミン酸デカルボキシラーゼ自己抗原関連疾患の診断及び処置方法
WO1992019972A1 (en) * 1991-05-03 1992-11-12 Novo Nordisk A/S Islet cell autoantigen (gad) for the detection of preclinical diabetes
AU671589B2 (en) * 1991-05-15 1996-09-05 Board Of Regents Of The University Of Washington, The Cloning and expression of human islet glutamic acid decarboxylase autoantigen
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
CA2074790A1 (en) * 1992-07-28 1994-01-29 H. Michael Dosch Methods for detecting pre-clinical iddm
DK0701569T3 (da) * 1992-12-03 2009-02-23 Univ California Forbedrede reagenser og fremgangsmåder til diagnosticering og behandling af diabetes og stiff man-syndrom
US5728385A (en) * 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US7008790B1 (en) 1993-08-12 2006-03-07 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
ATE178074T1 (de) * 1994-07-08 1999-04-15 Dartmouth College Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
US6509165B1 (en) 1994-07-08 2003-01-21 Trustees Of Dartmouth College Detection methods for type I diabetes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910700459A (ko) * 1988-12-13 1991-03-15 수잔 우레이 인슐린 의존성 진성당뇨병의 조기검진 및 치료를 위한 방법 및 조성물

Also Published As

Publication number Publication date
EP0543945A1 (de) 1993-06-02
ES2093714T3 (es) 1997-01-01
EP0543945B1 (de) 1996-10-16
JPH06500173A (ja) 1994-01-06
JP2649103B2 (ja) 1997-09-03
WO1992003733A1 (en) 1992-03-05
AU661828B2 (en) 1995-08-10
CA2089742A1 (en) 1992-02-18
AU8544891A (en) 1992-03-17
CA2089742C (en) 2002-05-14
DK0543945T3 (da) 1997-03-24
ATE144326T1 (de) 1996-11-15
DE69122761T2 (de) 1997-03-13
GR3022078T3 (en) 1997-03-31

Similar Documents

Publication Publication Date Title
DE69122761D1 (de) Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes
CA2005300A1 (en) Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
NO904001D0 (no) Fremgangsmaate og anordning for amperometrisk diagnoseanalyse.
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
ATE163767T1 (de) Verfahren zur diagnose und zur überprüfung von sepsis
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
DE69828645D1 (de) Gerät zur entnahme von interstitiellen flüssigkeit für diagnostische teste
EP1556405A4 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
NZ510703A (en) Assay for disease related conformation of a protein
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE174689T1 (de) Diagnose und behandlung von insulinabhängigem diabetes mellitus
JP2001513533A5 (de)
ATE191567T1 (de) Bestimmung von nukleären matrixproteinen in flüssigkeiten
Westhoff et al. The cardiovascular effects of upper-limb aerobic exercise in hypertensive patients
SE8701905D0 (sv) A method and a kit for the diagnosis of iga nephropathy
ATE362108T1 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von diabetes und assoziierten krankheiten mit beta-trp (mtr1 / ltrpc5 / trpm5)
DK0764273T3 (da) Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
ATE133205T1 (de) Diagnoseverfahren für infektionskrankheiten sowie verfahren zum nachweis und identifizierung von mikroorganismen
DE69224795D1 (de) 4Verfahren und Zusammensetzungen zur Vorbeugung, Diagnose und Behandlung seröser Entzündungen und damit verbundener Störungen
ATE80465T1 (de) Diagnose von fettleibigkeit, hervorgerufen durch eine genetische abnormalitaet, und verfahren zur therapeutischen behandlung von genetisch bedingter fettleibigkeit.
Firoozabadi The efficacy of detached mindfulness and distraction techniques in craving and relapse rates in opiate dependent male subjects
Von Rüden et al. Cyclosporin A treatment of children with severe atopic dermatitis improves quality of life of their mothers
Morris Recovering from coronary artery bypass graft surgery: Do depression, optimism, and coping predict quality of recovery?
UA34212A (uk) Спосіб оцінки результатів лікування хворих на ранні форми сифілісу

Legal Events

Date Code Title Description
8364 No opposition during term of opposition